# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
As of the data cut-off date, CAN-2409 treatment in NSCLC continued to exhibit a favorable safety and tolerability profile
Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.28) per share. This is a 6.67 percent increase over losses o...